Tin tức & Cập nhật
Lọc theo Chuyên ngành:
HIV intervention uptake remains low among transgender men; campaign helps
Transgender individuals, particularly transgender men (TGM), show poor acceptance of HIV prevention interventions (HPI) in the Philippines, according to a study presented at the AIDS 2022 conference in Montreal, Canada. Although some transgender individuals who prefer having sex with men make use of HPI, it remains relatively lower among TGM who have sex with men (SM).
HIV intervention uptake remains low among transgender men; campaign helps
05 Aug 2022
Treatment regimen based on small RNAi safe, effective in chronic hepatitis B
In patients with chronic hepatitis B (CHB), treatment with the small interfering RNA JNJ-3989, in combination with a nucleos(t)ide analogue (NA), safely reduces levels of the hepatitis B surface antigen (HBsAg) for up to almost a year after the last dose, a new study has found.
Treatment regimen based on small RNAi safe, effective in chronic hepatitis B
03 Aug 2022
Do cardiovascular drugs worsen COVID-19 outcomes?
Cardiovascular medications, such as angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blocker (ARBs) and anticoagulants, do not induce poor clinical outcomes in patients with COVID-19 and thus should not be discontinued, suggest the results of a meta-analysis.
Do cardiovascular drugs worsen COVID-19 outcomes?
03 Aug 2022
HBV coinfection among TB patients higher than expected
Coinfection with hepatitis B virus (HBV) among patients with tuberculosis (TB) appears to be 38-percent to 450-percent more prevalent than published estimates from the Polaris group of region-specific overall HBV prevalence, suggest the results of a meta-analysis.
HBV coinfection among TB patients higher than expected
01 Aug 2022
HK’s first territory-wide long COVID study to inform follow-up care
Researchers at the Chinese University of Hong Kong (CUHK) have rolled out the city’s first territory-wide study of long COVID to inform multidisciplinary follow-up care for thousands of COVID-19 survivors. Participants are also invited to a second-phase 3-year prospective study of the impact of gut dysbiosis on long COVID symptoms and the potential role of gut microbiome modulation in treatment of long COVID.
